Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.
Also called NCT05373680
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 118 participants
- Registry
-
NCT05373680
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05373680. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-04-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Empagliflozin
- Intervention (Other)
- Control
- Lead sponsor
- Tanta University
- Collaborator
- Mansoura University
Record details
- Record id
cardio:ct-nct05373680- Content hash
4e9ad1a9e227c4c1997b40c3bbec42625cf035eecf72370f802fa3bd8107f1a1